Tissue-type plasminogen activator (tPA) activates fibrinolysis and also suppresses innate immune system responses to LPS in bone marrow-derived macrophages (BMDMs) and in vivo in mice. The 
INTRODUCTION
The response to injury includes four phases: hemostasis, inflammation, proliferation, and remodeling. [1] [2] [3] By lysing fibrin clots, the fibrinolysis system resolves the hemostasis phase. Tissue-type plasminogen activator (tPA) is one of the two major activators of fibrinolysis in humans and rodents. 4, 5 We previously demonstrated that in addition to its role in fibrinolysis, tPA suppresses innate immune system responses Abbreviations: BMDMs, bone marrow-derived macrophages; EI, enzymatically inactive; IL-1ra, IL-1 receptor antagonist; MAP, mitogen-activated protein; NMDA-R, N-methyl-D-aspartate receptor; PA, plasminogen activator; PAR, protease-activated receptor; SFM, serum-free medium; tPA, tissue-type plasminogen activator to LPS in bone marrow-derived macrophages (BMDMs) and in vivo in mice. 6 The identified pathway did not require tPA proteinase activity but instead, interaction of tPA with the N-methyl-D-aspartate receptor (NMDA-R) in macrophages. tPA binding to the NMDA-R activates cell signaling and regulates cell physiology in multiple cell types. [7] [8] [9] [10] [11] [12] The ability of tPA to regulate innate immunity in LPS-treated macrophages provides an example in which a gene product that functions mainly in one phase of the response to injury regulates another.
have shown that plasmin activates NF-B and induces expression of proinflammatory cytokines in monocytes and macrophages. [13] [14] [15] [16] Plasmin also may contribute to the resolution of inflammation. 17 The protease activity of plasmin appears essential for its effects on cytokine expression. Plasminogen receptors, such as annexin A2/S100A10 complex, annexin A1, -enolase, and plasminogen-R TK , play a critical role in mediating the effects of plasmin in inflammation. 15, [17] [18] [19] [20] One function of plasminogen receptors may be to facilitate plasminogen activation and then deliver plasmin to cell-signaling receptors in the proteaseactivated receptor (PAR) family. 18, [21] [22] [23] [24] Alternative pathways by which plasmin may induce inflammation also have been described, such as by proteolytic activation of the chemokine, monocyte chemoattractant protein-1 (MCP-1/CCL2). 24, 25 In this study, we demonstrate that the activity of tPA as an inhibitor of the LPS response in BMDMs is apparently comprehensive; not only does tPA block expression of proinflammatory cytokines but also IL-10 and IL-1 receptor antagonist (IL-1ra), which demonstrate antiinflammatory activity. 26, 27 In the presence of plasminogen, the previously reported indistinguishable effects of EI-tPA and enzymatically active tPA on cytokine expression 6 are no longer observed because plasmin independently promotes expression of cytokines, including proinflammatory cytokines, by a pathway that is independent of the NMDA-R, and instead, dependent on PAR activation. tPA failed to inhibit the effects of plasmin on gene regulation in BMDMs; this result was probably explained by the inability of tPA to neutralize proinflammatory events mediated by PAR activation. This study provides the first evidence of specificity in the activity of tPA as an inhibitor of proinflammatory macrophage stimuli. The ability of plasmin to promote inflammatory cytokine expression, even in the presence of tPA, justifies testing EI-tPA, as the preferred form of tPA, as a candidate inhibitor of innate immunity.
MATERIALS AND METHODS

Proteins and reagents
Enzymatically active human tPA, which is produced in Chinese hamster ovary cells and 95% in the 2-chain form, and human EI-tPA, which carries the S478→A mutation and is 90% in the single-chain form, were from Molecular Innovations (Novi, MI, USA). Glu-plasminogen was purified from human plasma as previously described. 28 The purified plasminogen preparations studied here were unresolved mixtures of the two major glycoforms. Plasmin (>10 IU/mL), which was preactivated with immobilized low molecular weight urokinase, was from 
BMDM cultures
Bone marrow cells were isolated from the femurs of 16-week-old wild-type C57BL/6J male mice, as previously described. 29 these experiments assured that bovine plasminogen was not inadvertently present during the treatments. All reagents used to assess pathways involved in the response to tPA and plasmin had no effect on cell viability at the concentrations studied, as determined by MTT assay (Invitrogen).
Plasminogen activation in association with BMDMs
BMDMs were seeded in 48-well plates at a density of 10 5 cells/well. 
Analysis of cytokines in conditioned medium
BMDMs were transferred to SFM for 30 min and then treated with plasminogen and/or tPA as indicated for 3 h. Serum-free conditioned medium was harvested and assayed for mouse TNF-protein and IL-6 protein using Quantikine ELISA systems (R&D System).
Analysis of cytokine mRNA expression
RNA was isolated using the NucleoSpin RNA kit (Macherey-Nagel) and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad).
Reverse transcription quantitative PCR (RT-qPCR) was performed to determine the relative abundance of mRNAs encoding TNF-, IL-1 , IL-6, CCL2, IL-10, and IL-1ra using TaqMan gene expression products (Thermo Scientific), as previously described. 29 Changes in mRNA expression were calculated using the 2 −ΔΔCt method and GAPDH mRNA as an internal normalizer. 
Phosphoprotein proteome profiling
BMDMs were transferred to SFM for 30 min and treated with active tPA (12 nM) and plasminogen (200 nM) or with vehicle for 1 h.
Cell extracts were prepared using lysis buffer provided in the Proteome Profiler Human Phospho-Kinase Array kit (R&D Systems).
An equivalent amount of cellular protein (400 g) was incubated with the 2 nitrocellulose membranes. Phosphorylated proteins were detected using biotinylated detection antibodies. Although this array was initially developed to identify phosphoproteins in human proteins, we demonstrated excellent cross-reactivity with rodent proteins by comparing human and rat Schwann cells. 30 
Statistics
Statistical analysis was performed using GraphPad Prism 5.0. Results are presented as the mean ± SEM. Each replicate was performed using BMDM cultures from a separate mouse. RT-qPCR data were analyzed by one-way ANOVA followed by Bonferroni's multiple comparison test (*P < 0.05; **P < 0.01; ***P < 0.001).
RESULTS
EI-tPA blocks LPS-induced cytokine expression in the presence of plasminogen
The first objective of this study was to determine whether plasminogen affects the ability of tPA to regulate proinflammatory cytokine expression by BMDMs in response to LPS. When enzymatically active tPA (12 nM) and increasing concentrations of plasminogen were incubated with BMDMs in SFM supplemented with plasmin-specific chromogenic substrate, plasminogen activation was observed and the amount of plasmin formed was a function of the plasminogen concentration (Fig. 1A) . In the absence of tPA, plasminogen activation was extremely weak or entirely absent over the 70 min monitoring period, indicating that our plasminogen preparations were not contaminated with plasmin and the BMDMs do not independently generate significant levels of plasminogen activators (PAs) in the absence of offsetting PA inhibitors, such as PAI-1 (Fig. 1B) . Plasminogen activation also was not detected when cells were incubated with 12 nM EI-tPA and increasing concentrations of plasminogen (Fig. 1C) .
Because EI-tPA did not activate plasminogen, to begin, we studied the effects of plasminogen on the activity of EI-tPA in cytokine mRNA expression experiments. BMDMs were treated with EI-tPA alone or in the presence of 20-500 nM plasminogen for 3 h. As a control, BMDMs were exposed to LPS (0.1 g/mL). The 3 h exposure time was selected, as opposed to 6-8 h, as in our previous studies, 6, 29 to avoid changes in cell adhesion or survival that may result from prolonged exposure to plasminogen or plasmin. LPS significantly increased expression of TNF-, IL-1 , IL-6, and CCL2, as anticipated ( Fig. 2A) . In the absence of LPS, EI-tPA did not significantly increase cytokine expression and this result was conserved in cells treated with EI-tPA and plasminogen.
Next, we studied the effects of EI-tPA on cytokine expression in cells treated simultaneously with LPS. In the absence of plasminogen, EI-tPA . RT-qPCR was performed to compare mRNA levels for TNF-, IL-1 , IL-6, CCL2, IL-10, and IL-1ra (mean ± SEM; n = 5 in panels A and B and 3 in panel C; ***P < 0.001; N.S., not statistically significant; one-way ANOVA with Bonferroni's post hoc test). The presented results show "fold increase" in mRNA expression compared with cultures treated with vehicle (no LPS, EI-tPA, or Plg) (12 nM) reversed the effects of LPS (0.1 g/mL) on expression of TNF-, IL-1 , IL-6, and CCL2 (Fig. 2B ), confirming our earlier results. 6 EItPA also reversed the effects of LPS on expression of IL-10 and IL-1ra (Fig. 2C) , gene products with known anti-inflammatory activities. 26, 27 It thus appears that EI-tPA neutralizes the response to LPS comprehensively, and not just the effects of LPS on expression of proinflammatory mediators. Plasminogen at concentrations up to 500 nM failed to affect the efficacy of EI-tPA in reversing LPS-induced gene regulatory events. These results demonstrate that the activity of EI-tPA as an antagonist of the macrophage response to LPS is conserved in the presence of plasminogen.
Plasminogen activation reverses the effects of enzymatically active tPA on LPS-induced cytokine expression
To determine whether plasminogen regulates cytokine expression by BMDMs in the absence of tPA, cells were treated with increasing concentrations of plasminogen or with LPS (0.1 g/mL) as a positive control. Fig. 3A shows that, in the absence of tPA, plasminogen did not significantly regulate cytokine expression. When BMDMs were treated simultaneously with LPS and 20-500 nM plasminogen, plasminogen did not regulate the LPS response (Fig. 3B) . , LPS plus 12 nM enzymatically active tPA (EA-tPA), or LPS plus 12 nM EA-tPA and increasing concentrations of plasminogen (Plg) for 3 h. RT-qPCR was performed to compare mRNA expression of TNF-, IL-1 , IL-6, and CCL2 (mean ± SEM; n = 4-6; *P < 0.05, **P < 0.01, ***P < 0.001; N.S., not statistically significant; one-way ANOVA with Bonferroni's post hoc analysis). The presented results show "fold increase" in mRNA expression compared with cultures treated with vehicle Next, BMDMs were treated with 0.1 g/mL LPS, in the presence and absence of enzymatically active tPA and increasing concentrations of plasminogen. LPS induced expression of the mRNAs encoding TNF-, IL-1 , IL-6, and CCL2 and, in the absence of plasminogen, tPA reversed the effects of LPS on cytokine expression (Fig. 3C ). tPA retained its activity when 20-80 nM plasminogen was present. By contrast, when 200-500 nM plasminogen was present, the ability of active tPA to block cytokine expression in response to LPS was reversed. In these cells, expression of TNF-, IL-1 , IL-6, and CCL2 was unchanged, compared with cells treated with LPS alone, or slightly increased.
Next, we treated BMDMs with active tPA and 20-500 nM plasminogen, in the absence of LPS. When the plasminogen concentration was 200-500 nM, expression of proinflammatory cytokines increased to about the level observed with 0.1 g/mL LPS alone (Fig. 4A-D) .
Because, plasminogen failed to induce cytokine expression in the absence of tPA, we hypothesized that plasminogen activation was necessary. Fig. 4E and F show that 12 nM tPA and 200 nM plasminogen increased expression of IL-10 and IL-1ra, similarly to LPS.
To confirm that active tPA and plasminogen induce cytokine expression in BMDMs at the protein level, we analyzed conditioned medium samples by ELISA. Significantly increased levels of TNF- (Fig. 4G ) and IL-6 (Fig. 4H) were detected in conditioned medium from cells treated with tPA and 200 nM plasminogen. We did not examine IL-1 protein given the complex system of inflammasome proteins that regulate IL-1 protein secretion. 31 ACA binds to the lysine-binding sites of plasminogen and inhibits binding of plasminogen to cell-surface receptors. 32 In doing so, ACA may disrupt interactions that promote plasminogen activation. We Aprotinin is a 58-amino acid proteinase inhibitor from bovine pancreas and a naturally occurring plasmin inhibitor. 33 Aprotinin blocked the increase in TNF-mRNA expression caused by active tPA plus 200 nM plasminogen (Fig. 5E ). This result supports the hypothesis that plasmin enzyme activity is necessary for the proinflammatory response observed when tPA and plasminogen are added to cultures of BMDMs. To confirm this hypothesis, we examined the ability of preactivated plasmin to induce TNF-expression in BMDMs in the absence tPA. The plasmin was generated using low molecular weight urokinase coupled to Sepharose and thus, not contaminated with PAs. Fig. 5F shows that preactivated plasmin significantly increased TNF-mRNA expression and the response appeared plasmin concentration dependent. Importantly, when cells were treated with EI-tPA together with preactivated plasmin, the EI-tPA failed to block the increase in TNFexpression induced by preactivated plasmin.
Involvement of cell-signaling receptors in the response of BMDMs to plasmin
We previously demonstrated that BMDMs express the NMDA-R, which serves as an essential receptor in the pathway by which tPA suppresses cytokine expression by BMDMs in response to LPS. 6 We therefore tested whether the NMDA-R is involved in the proinflam- Expression of the mRNAs encoding TNF-, IL-1 , IL-6, and CCL2 was determined (mean ± SEM; n = 3-4; *P < 0.05, ***P < 0.001; one-way ANOVA with Bonferroni's post hoc test). (E) BMDMs were treated for 3 h with EA-tPA (12 nM) plus Plg (200 nM), aprotinin alone (33 Unit/mL), or EA-tPA, plasminogen plus aprotinin. RT-qPCR was performed to compare mRNA levels for TNF-(mean ± SEM; n = 4; ***P < 0.001; one-way ANOVA with Bonferroni's post hoc analysis). (F) BMDMs were treated for 3 h with the indicated concentrations of preactivated plasmin (Pm) in the presence or absence of EI-tPA. TNF-mRNA was determined (n = 4). The presented results show "fold increase" in mRNA expression compared with cultures treated with vehicle (*P < 0.05, **P < 0.01; statistical analysis is relative to the vehicle control)
F I G U R E 6
The NMDA-R is not required for the proinflammatory response to plasmin. BMDMs were pretreated with MK-801 (1.0 M) or vehicle for 30 min and then for 3 h with 12 nM enzymatically active tPA (EA-tPA), EA-tPA and plasminogen (Plg; 200 nM), Plg, or vehicle. Expression of the mRNAs encoding TNF-, IL-1 , IL-6, and CCL2 was determined (mean ± SEM; n = 6; **P < 0.01, ***P < 0.001; N.S., not statistically significant; one-way ANOVA with Bonferroni's post hoc test). In separate control experiments (not shown), we demonstrated that the MK-801 blocked the ability of 12 nM EI-tPA to inhibit cytokine expression induced by LPS (0.1 g/mL) activity against other PARs. 35 Like SCH 79797, RWJ 56110 blocked the increase in expression of TNF-, IL-1 , IL-6, and CCL2 caused by active tPA plus 200 nM plasminogen (Fig. 7B) . RWJ 56110 did not affect cytokine expression when added to BMDM cultures alone. RWJ 56110 also did not significantly affect cytokine expression by BMDMs treated with 0.1 g/mL LPS.
tPA and plasmin have distinct effects on cell signaling in BMDMs
We performed studies to determine how plasminogen activation (Fig. 8A ) as anticipated; these changes report NF-B activation. 36 In the absence of plasminogen, enzymatically active tPA reversed the effects of LPS on I B phosphorylation and its total abundance, as previously reported. 6 By contrast, when BMDMs were treated with active tPA and 200 nM plasminogen, in the presence of LPS or in its absence, I B was phosphorylated and the total abundance of I B was decreased. Thus, plasmin appears to independently promote I B phosphorylation in BMDMs even though tPA is present.
Next, we examined cell signaling in response to plasmin in BMDMs in an unbiased manner using an array platform that detects multiple distinct protein phosphorylation events. BMDMs were treated with enzymatically active tPA (12 nM) and 200 nM plasminogen for 1 h.
Protein extracts were then subjected to analysis (Fig. 8B) . Phosphoepitopes that were increased at least 1.6-fold are enclosed in boxes.
The results are summarized in Fig. 8C . The major mitogen-activated protein (MAP) kinases, ERK1/2, c-Jun N-terminal kinase, and p38 MAP kinase were phosphorylated in plasmin-treated cells, together with the c-Jun N-terminal kinase substrate, c-Jun. CREB is a transcription factor phosphorylated downstream of diverse kinases including ERK1/2 and p38 MAP kinase. 37 Phosphorylation of Akt at S473 is considered an mTORC2 event, required for full Akt activation. 38 p70 S6 kinase is a downstream mediator of PI3K-Akt signaling involved in cell survival and growth. 39 p70 S6 kinase activation also has been implicated in inflammatory cytokine production by macrophages. 40, 41 Because the array analysis is performed only once, validation studies were performed using conventional immunoblotting to examine phosphorylation of the 3 MAP kinases. These validation studies and separate experiments examining I B phosphorylation included incubations to test whether inhibitors that block cytokine expression in response to plasmin also block plasmin-initiated cell signaling. Fig. 8D shows that plasmin-induced I B phosphorylation was blocked by SCH 79797 and RWJ 56110. 
tPA fails to reverse cytokine expression caused by PAR-1 agonist peptide
The results presented thus far suggested that plasmin induces proinflammatory cytokine expression by activating a PAR, and most likely PAR-1. Because EI-tPA failed to inhibit the effects of preactivated plasmin on cytokine expression, we tested whether tPA is ineffective at neutralizing proinflammatory responses mediated by PARs.
BMDMs were treated with PAR-1 agonist peptide/TFLLR in the presence or absence of tPA. Fig. 9 shows that TFLLR induced expression of TNF-, IL-1 , IL-6, and CCL2, whereas the control peptide, RLLFT, did not. When either enzymatically active tPA or EI-tPA was added together with TFLLR, cytokine expression was not inhibited. These results demonstrate that tPA is not effective in regulating PAR-induced cytokine expression in BMDMs and provide the first evidence for specificity in the anti-inflammatory activity of tPA. (12 or 24 nM) . Separate cultures were treated with RLLFT (10 M) as a negative control peptide. Expression of the mRNAs encoding TNF-, IL-1 , IL-6, and CCL2 was determined (mean ± SEM; n = 4; **P < 0.01, ***P < 0.001; N.S., not statistically significant; one-way ANOVA with Bonferroni's post hoc test). The presented results show "fold increase" in mRNA expression compared with cultures treated with vehicle
DISCUSSION
tPA is an FDA-approved drug for stroke. 42 The recently discovered activity of tPA as an inhibitor of innate immune system responses to LPS 6 is thus of considerable interest. EI-tPA neutralized the toxicity of LPS when administered to mice at approximately 2-times the dose of tPA recommended for patients with stroke. 6 Because the effects of EI-tPA on hemostasis should be greatly attenuated compared with the active enzyme, higher doses of EI-tPA may be feasible in experiments testing the activity of EI-tPA in immunity.
Our research suggesting that tPA may antagonize the response of macrophages to stimuli that activate the innate immune system 6, 29 raises important questions regarding how tPA and its major substrate, plasminogen, interact in immunity. A robust body of literature indicates that plasmin regulates cell signaling and gene expression in monocytes and macrophages and may contribute to a proinflammatory state. [13] [14] [15] [16] The major objective of this study was to consider the activities of tPA and plasminogen as regulators of innate immunity in concert.
We applied a previously described mouse BMDM cell culture model system 6, 29 and demonstrated that, in the absence of plasminogen, tPA not only inhibits expression of proinflammatory cytokines by BMDMs in response to LPS, but also IL-10 and IL-1ra. Thus, tPA appears to inhibit the macrophage response to LPS comprehensively.
When BMDMs were treated with enzymatically active tPA and sufficiently high concentrations of plasminogen, plasmin was generated EI-tPA retained its anti-inflammatory activity when added to cultures together with LPS, even in the presence of the highest concentrations of plasminogen, a result that reflects the inability of EI-tPA to activate plasminogen. We conclude that EI-tPA is the preferred reagent, as opposed to enzymatically active tPA, to assess the activity of tPA as a candidate anti-inflammatory agent in animal model systems.
The effects of tPA and plasmin on proinflammatory cytokine expression by BMDMs are mediated by distinct receptor systems. MK-801 blocks the activity of tPA, as a neutralizer of LPS 6 ; however, MK-801 had no effect on cytokine expression in response to plasmin. The NMDA-R, which plays an essential role in mediating many cellular activities of tPA, 6, 11, 12 is not involved in the response of BMDMs to plasmin. By contrast, the effects of plasmin on BMDM gene expression were blocked by ACA, aprotinin, and 2 separate PAR-1-selective PAR antagonists. These results fit a model in which plasmin is generated by enzymatically active tPA in association with cellular receptors in a facilitated reaction that is inhibited by ACA. Once plasmin is generated, it cleaves a PAR, activating cell-signaling downstream of this G protein-coupled receptor. If plasmin is inhibited by aprotinin or if PAR inhibitors are added, the response to plasmin is blocked. This model is supported by studies demonstrating that thrombin-activated cell signaling through PAR-1 is proinflammatory, 43, 44 like the plasmininitiated response described here.
The activity of PARs as plasmin response mediators is not straightforward because we and others have reported that plasmin may desensitize these receptors. 45, 46 At the biochemical level, this paradox is explained by the fact that plasmin cleaves PAR-1 at the same site as thrombin, in a reaction that activates cell signaling, and at sites distal to the thrombin cleavage site. The latter reactions inactivate PAR-1. 47 The predominant activity of plasmin, observed in different experimental model systems, may reflect the abundance of PARs on the cell surface and whether alternative PAR activators are present.
It is also possible that activation of PARs by plasmin 18, [21] [22] [23] [24] reflects selective presentation of PAR peptide bonds to plasmin that is bound to cell-surface plasminogen receptors.
Because of evidence implicating PARs in plasmin responses in monocytes and macrophages, the inability of EI-tPA to inhibit cytokine expression induced by preactivated plasmin was examined in experiments with PAR-1 agonist peptide. TFLLR increased proinflammatory cytokine expression in BMDMs and both active tPA and EI-tPA failed to reverse this response. These data provide the first evidence for specificity in the anti-inflammatory activity of tPA. Whether tPA is effective in suppressing cytokine expression depends on the proinflammatory signal and the receptor system engaged.
The inability of BMDMs to mediate plasminogen activation in the absence of exogenously added tPA demonstrates that these cells do not produce large amounts of PAs in the absence of endogenous PA inhibitors. When tPA and 80 nM plasminogen were added to BMDM cultures, plasmin generation was detected by chromogenic substrate assay; however, consistently, the amount of plasmin generated appeared insufficient to induce cytokine expression or reverse the activity of tPA as an inhibitor of LPS. These results suggest that there may be a threshold concentration of plasmin required for generating a response. This hypothesis merits further investigation.
The identification of distinct receptor systems for tPA and plasmin, which regulate macrophage activation and innate immunity, supports models linking hemostasis and inflammation. Understanding these receptor systems may be important not only in the response to injury but also in numerous diseases in which inflammatory pathways are inappropriately activated.
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